The latest pricing policy and price adjustment trends of capmatinib in 2025

Capmatinib (Capmatinib), as a new type of MET inhibitor, has successfully entered the domestic market in 2025 and has been included in the national medical insurance directory. It is pan>METExon14 Skipping mutations provide new treatment options for patients with advanced or metastatic non-small cell lung cancer (NSCLC). Due to its unique mechanism of action and significant efficacy in the field of targeted therapy, capmatinib has received great attention from clinical and patient groups after its domestic launch. However, due to the relatively short time to market, it is still difficult to obtain the drug directly in China, and some patients may need to obtain it through formal overseas channels.

In terms of price policy, after the domestic capmatinib original drug is included in the medical insurance, patients can enjoy medical insurance reimbursement, which greatly reduces the economic burden of medication. The domestic price ranges from a few thousand yuan to 10,000 yuan, and the specific reimbursement amount varies depending on regional medical insurance policies and the patient's personal circumstances. Medical insurance coverage not only allows patients to obtain drugs more conveniently, but also promotes the popularization and application of targeted drugs in clinical practice, thus improving the treatment compliance of patients with advanced lung cancer.

For overseas markets, the price of capmatinib varies greatly. The price of original drugs is usually higher, mostly around tens of thousands of yuan, while the price of generic drugs is more affordable. For example, the price of the Laos version of capmatinib generic drug is only more than 2,000 yuan, and its drug ingredients are basically the same as the original drug. This price difference provides more options for patients with limited financial conditions, and also promotes the gradual balance of global targeted drug prices.

Looking forward to the future, with the promotion of capmatinib in the domestic market and the gradual improvement of medical insurance policies, its price adjustment trend may become more stable. On the one hand, the expansion of medical insurance reimbursement coverage will further reduce patients’ out-of-pocket expenses; on the other hand, the possibility of overseas generic drugs entering the domestic market will also have a certain regulatory effect on prices. Overall, the price policy and market trends of capmatinib show the development direction of "ensuring accessibility and controlling economic burden", providing a more feasible treatment approach for METmutation-positive late-stage NSCLC patients.

Reference link: https://www.drugs.com